Semaglutide associated with lowe r risk of suicidal ideations comp ared to other treatments prescrib ed for obesity or type 2 diabetes

Niaid.nih.gov

Click here to subscribe to Niaid.nih.gov

10 months ago

Html
Text

Having trouble viewing this email? View it as a Web page.

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

Semaglutide associated with lower risk of suicidal ideations compared to other treatments prescribed for obesity or type 2 diabetes 01/05/2024 08:45 AM EST
NIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than those given other medications.

Update Your E-mail Address | Add Subscriptions | Unsubscribe All

If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view ourFrequently Asked Questions page, our Health Information page, or Search our website.

This service is provided to you by the National Institutes of Health.
NIHTurning Discovery Into Health

This email was sent to newsletter@newslettercollector.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) 9000 Rockville Pike Bethesda MD 20892 301-496-4000 / TTY 301-402-9612

Share on

Other newsletters from Niaid.nih.gov

Register to Join! NIH World AIDS Day Event Niaid.nih.gov
23 hours ago
Regstrese para unirse! Evento d el Da Mundial del SIDA de los NIH Niaid.nih.gov
23 hours ago
Newer epilepsy medications used during pregnancy do not affect neurological development in children Niaid.nih.gov
Yesterday at 16:35

More newsletters from Niaid.nih.gov

Semaglutide associated with lowe r risk of suicidal ideations comp ared to other treatments prescrib ed for obesity or type 2 diabetes

Share on

Other newsletters from Niaid.nih.gov

Related newsletters